The abstract is read at the publisher; the summary is JClub's.
A single dose of NmCV-5 in 2–29-year-olds in Mali and The Gambia retained rSBA titers ≥128 at 12 months for serogroups A, Y, W, and X, with 90.9% for C.
- Why it matters: Epidemic meningitis in Sub-Saharan Africa requires vaccines that maintain protective immune responses beyond the initial post-vaccination period.
- What they did: In a phase 3 observer-blind trial, 786 participants were tested by rabbit complement serum bactericidal assay at 6 and 12 months after receiving NmCV-5 or MenACYW-D.
- The result: NmCV-5 showed 100% retention for A, Y, and W, 99.8% for X, and 90.9% for C, while GMTs declined by 12 months; longer follow-up is needed to project protection duration.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.